Skip to main content
SpringerLink
Log in

Key Advances in Clinical Cardiology

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Multiple key cardiology trials with the potential to change practice or advance understanding have been presented over the past 12 months at international meetings, including the American College of Cardiology (ACC, Chicago, USA, March 2012), European Association for Percutaneous Cardiovascular Interventions (EuroPCR, Paris, France, May 2012), European Society of Cardiology (ESC, Munich, Germany, August 2012), Transcatheter Cardiovascular Therapeutics (TCT, Miami, USA, October 2012), and the American Heart Association (AHA, Los Angeles, USA, November 2012). In this paper, the authors describe and place in clinical context new acute coronary syndrome data, including use of oral antiplatelets and anticoagulants (prasugrel, rivaroxaban, vorapaxar), personalized antiplatelet therapy guided by platelet aggregometry, glucose-insulin-potassium infusion, and changing trends in myocardial infarction. New trial data are also described for interventional cardiology (revascularization in multivessel disease, fractional flow reserveguided intervention, radial access, bioabsorbable polymer stents, drug-eluting balloons, intraaortic balloon pump use, transcatheter aortic valve implantation), in heart failure (copeptin, angiotensin receptor neprilysin inhibition, aldosterone blockade in diastolic heart failure, biventricular pacing), atrial fibrillation (surgical ablation, antithrombotic strategy after stenting), implantable defibrillator use, and in prevention (renal denervation in hypertension, dalcetrapib, lomitapide, proprotein convertase subtilisin/kexin type 9 in dyslipidemia, insulin glargine/fish oils, and bariatric surgery in diabetes).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roe MT, Armstrong PW, Fox KAA, et al.; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Eng J Med. 2012:367:1297–1309.

    Article  CAS  Google Scholar 

  2. Clinical Trial Results. Prasugrel vs. clopidogrel for acute coronary syndromes patients managed with revascularization — the TRILOGY ACS trial. Available at: http://clinicaltrialresults.org/Slides/ESC%202012/TRILOGY%20ACS%20LBCT%20Presentation%20Draft%208.25.12%20Final%20 Version.ppt. Accessed Feb 18 2013.

  3. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012:366:9–19.

    Article  PubMed  CAS  Google Scholar 

  4. Tricoci P, Huang Z, Held C, et al.; TRA2P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with prior myocardial infarction. N Engl J Med. 2012;366:20–33.

    Article  PubMed  CAS  Google Scholar 

  5. Marcucci R, Gori M, Valenti R, et al. Global high on-treatment platelet reactivity identifies patients at high risk of ischemic events: data from RECLOSE 2-ACS study. Oral Presentation. European Society of Cardiology; Aug 2012; Munich.

    Google Scholar 

  6. Gurbel PA, Erlinge D, Ohman EM, et al.; TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization. The TRILOGY ACS platelet function substudy. JAMA. 2012;308:1785–1794.

    Article  PubMed  CAS  Google Scholar 

  7. Collet JP, Cuisset T, Range G, et al.; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–2109.

    Article  PubMed  CAS  Google Scholar 

  8. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes. JAMA. 2012;307:1925–1933.

    Article  PubMed  CAS  Google Scholar 

  9. Clinical Trial Results. Results of the IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care) Trial: a double-blinded randomized controlled trial of intravenous glucose, insulin & potassium (GIK) for acute coronary syndromes in emergency medical services. Available at: http://clinicaltrialresults.org/Slides/ACC2012/Selker_IMMEDIATEtrial.pdf. Accessed Feb 18 2013.

  10. Puymirat E, Simon T, Steg PG, et al.; USIK USIC 2000 Investigators; FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998–1006.

    Article  PubMed  CAS  Google Scholar 

  11. Farkouh ME, Domanski M, Sleep LA, et al.; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375–2384.

    Article  PubMed  CAS  Google Scholar 

  12. de Bruyne B, Pijls N, Kalesan B, et al.; FAME 2 Trial Investigators. Fractional flow reserve guided PCI versus medical treatment in stable coronary disease. N Engl J Med. 2012;367:991–1001.

    Article  PubMed  Google Scholar 

  13. Fearon WK. A prospective, randomized trial evaluating the cost-effectiveness of FFR-guided PCI in patients with stable coronary artery disease. Oral presentation. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium; October 22–26, 2012; Miami, FL.

  14. Serruys P. LEADERS: 5-year follow-up. Oral presentation. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium; October 22–26, 2012; Miami, FL.

  15. Rüber L, Kelbæk H, Ostojic M, et al.; COMFORTABLE AMI Trial Investigators. Effect of Biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308:777–787.

    Article  Google Scholar 

  16. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer Biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, noninferiority trial. Lancet. 2013;381:651–660.

    Article  PubMed  CAS  Google Scholar 

  17. Serra A. VALENTINES II registry. Oral Presentation. Cardiovascular Research Technologies; February 4–7, 2012; Washington, DC.

    Google Scholar 

  18. Bernat I. STEMI-RADIAL: A prospective, randomized trial of radial vs. femoral access in patients with ST-segment elevation myocardial infarction. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium; October 22–26, 2012; Miami, FL.

  19. Hamon M, Pristipino C, Di Mario C, et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. EuroIntervention. 2013;pii:20130115-02.

    Google Scholar 

  20. Dewilde W, Oirbans T, Verheugt F, et al. What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing. Presented at: European Society of Cardiology 2012 Congress; August 29, 2012; Munich, Germany.

  21. Clinical Trial Results. The WOEST Trial: First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Available at: http://www.clinicaltrialresults.org/Slides/ESC%202012/Ten%20Berg_ESC%20WOEST%20 2012.ppt. Accessed Feb 18 2013.

  22. Thiele H, Zeymer U, Neumann FJ, et al.; IABPSHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock (SHOCK II). N Engl J Med. 2012;367:1287–1296

    Article  PubMed  CAS  Google Scholar 

  23. Perera D, Stables R, Clayton T, et al.; BCIS-1 Investigators. Long-term mortality data from the Balloon Pump-Assisted Coronary Intervention Study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013;127:207–212.

    Article  PubMed  Google Scholar 

  24. Smith C, Leon L, Mack MJ, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aorticvalve replacement in high-risk patients. N Engl J Med. 2011;364:2187–2198.

    Article  PubMed  CAS  Google Scholar 

  25. Susheel K, Kodali, Mathew R, et al.; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686–1695.

    Article  Google Scholar 

  26. Keller T, Tizkas S, T Zeller, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55:2096–2106.

    Article  PubMed  CAS  Google Scholar 

  27. Berliner D, Deubner N, Fenske W, et al. Copeptin in heart failure: associations with clinical characteristics and prognosis. European Society of Cardiology 2012 Congress; August 29, 2012; Munich, Germany. Abstract 527.

  28. Solomon SD, Zile M, Pieske B, et al.; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387–1395.

    Article  PubMed  CAS  Google Scholar 

  29. Edelmann F, Wachter R, Schmidt A, et al. Aldosterone receptor blockade in diastolic heart failure. Presented at: European Society of Cardiology 2012 Congress; August 29, 2012; Munich, Germany.

  30. Budera P, Straka Z, Osmancik P, et al. PRAGUE-12 trial: randomized open multicenter study comparing cardiac surgery with MAZE versus cardiac surgery without MAZE in patients with coronary and/or valvular heart disease and with atrial fibrillation. Presented at: European Society of Cardiology 2012 Congress; August 29, 2012; Munich, Germany.

  31. Curtis AB. Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block (BLOCK HF) trial. Oral presentation. American Heart Association; November 3–7, 2012; Los Angeles, CA.

  32. Moss AJ, Schuger C, Beck CA, et al.; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–2283.

    Article  PubMed  CAS  Google Scholar 

  33. Lonn E. Glucose reduction and atherosclerosis continuing evaluation. Oral presentation: European Society of Cardiology 2012 Congress; August 29, 2012; Munich, Germany.

  34. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigator-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009;158:1–7.

    Article  PubMed  Google Scholar 

  35. Krum H, Schlaich M, Schmieder R, et al. Renal sympathetic denervation for the treatment of resistant hypertension: 18 month results from the SYMPLICITY HTN randomized control trial. Presented at: European Society of Cardiology 2012 Congress; August 29, 2012; Munich, Germany.

  36. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–1576.

    Article  PubMed  CAS  Google Scholar 

  37. Schwartz GG, Olsson AG, Abt M, et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.

    Article  PubMed  CAS  Google Scholar 

  38. Cuchel M, Meagher E, du toit Theron HDT, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–46.

    Article  PubMed  CAS  Google Scholar 

  39. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Craigavon Cardiac Centre, Craigavon Hospital, Southern Trust, Northern Ireland, BT63 5QQ, UK

    Michael Connolly & Ian B. A. Menown

Authors
  1. Michael Connolly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian B. A. Menown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian B. A. Menown.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Connolly, M., Menown, I.B.A. Key Advances in Clinical Cardiology. Adv Therapy 30, 369–386 (2013). https://doi.org/10.1007/s12325-013-0024-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-013-0024-5

Keywords

Search

Navigation